Skip to main content
SpringerLink
Log in

High-Throughput Screening in Industry

  • Chapter
Anticancer Drug Development Guide

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Drug discovery operations have been transformed over the past 20 yr by a series of technological innovations and scientific advances that the pharmaceutical industry has been quick to exploit. The trend has been to embrace automation and high-throughput techniques and to integrate research functions into a consolidated framework for drug discovery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine, 5th ed. Toronto: BC Decker, 2000.

    Google Scholar 

  2. Harris S. Transgenic knockouts as part of high-throughput, evidence-based target selection and validation strategies. Drug Discov Today 2002; 6: 628–636.

    Article  Google Scholar 

  3. Dean NM. Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr Opin Biotechnol 2001; 12: 622–625.

    Article  PubMed  CAS  Google Scholar 

  4. Goodchild J. Hammerhead ribozymes for target validation. Expert Opin Ther Targets 2002; 6: 235–247.

    Article  PubMed  CAS  Google Scholar 

  5. Goodchild J. Hammerhead ribozymes: biochemical and chemical considerations. Curr Opin Mol Ther 2000; 2: 272–281.

    PubMed  CAS  Google Scholar 

  6. Hannon GJ. RNA interference Nature 2002; 418:244–251

    Google Scholar 

  7. Lipinski CA, Lombardo F, Dominy BE, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3–25.

    Article  CAS  Google Scholar 

  8. Spalding DJM, Harker AJ, Bayliss MK. Combining high-throughput pharmacokinetic screens at the hits-to-leads stage of drug discovery. Drug Discov Today 2000; 5 (suppl): S70–76.

    Article  CAS  Google Scholar 

  9. Clark DE, Pickett SD. Computational methods for the prediction of `drug-likeness.’ Drug Discov Today 2000; 5:49–58

    Google Scholar 

  10. Watt AP, Morrison D, Evans DC. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. Drug Discov Today 2000; 5: 17–24.

    Article  PubMed  CAS  Google Scholar 

  11. Rowland RS. Using X-ray crystallography in drug discovery. Curr Opin Drug Discov Devel 2002; 5: 613–619.

    PubMed  CAS  Google Scholar 

  12. Leach AR, Hann MM. The in silico world of virtual libraries Drug Discov Today 2000; 5:326–336

    Google Scholar 

  13. Bajorath J. Integration of virtual and high-throughput screening Nat Rev Drug Discov 2002; 1:882–894

    Google Scholar 

  14. Dhundale A, Goddard C. Reporter gene assays in the high throughput laboratory: a rapid and robust first look? J Biomol Screen 1996; 1: 115–118.

    Article  CAS  Google Scholar 

  15. Pope AJ, Haupts UM, Moore KJ. Homogeneous fluorescence readouts for miniaturized high-throughput screening: theory and practice. Drug Discov Today 1999; 4: 350–362.

    Article  PubMed  CAS  Google Scholar 

  16. Hemmilä I, Webb S. Time-resolved fluorometry: an overview of the labels and core technologies for drug screening applications. Drug Discov Today 1997; 2: 373–381.

    Article  Google Scholar 

  17. Cook ND Scintillation proximity assay-a versatile high throughput screening technology Drug Discov Today 1996; 1:287–294

    Google Scholar 

  18. Glickman JF, Wu X, Mercuri R, et al. A comparison of ALPHAScreen, TR-FRET and TRF as assay methods for FXR nuclear receptors. J Biomol Screen 2002; 7: 3–10

    Article  PubMed  CAS  Google Scholar 

  19. Kolb AJ, Kaplita PV, Hayes DJ, et al. Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Discov Today 1998; 3: 333–342

    Article  CAS  Google Scholar 

  20. Earnshaw DL, Pope AJ. FlashPlate scintillation proximity assays for characterization and screening of DNA polymerase, primase, and helicase activities. J Biomol Screen 2001; 6: 39–46.

    PubMed  CAS  Google Scholar 

  21. Berg M, Undisz K, Thiericke R, Moore T, Posten C. Miniaturization of a functional transcription assay in yeast (human progesterone receptor) in the 384- and 1536-well plate format. J Biomol Screen 2000; 5: 71–76.

    Article  PubMed  CAS  Google Scholar 

  22. Ramm P. Imaging systems in assay screening. Drug Discov Today 1999; 4: 401–410.

    Article  PubMed  CAS  Google Scholar 

  23. Kain SR. Green fluorescent protein (GFP): applications in cell-based assays for drug discovery Drug Discov Today 1999; 4:304–312

    Google Scholar 

  24. Liptrop C. High content screening-from cells to data to knowledge. Drug Discov Today 2001; 6: 832–834.

    Article  Google Scholar 

  25. Moore KJ, Turcone S, Ashman S, et al. Single molecule detection techniques in miniaturized high-throughput screening: fluorescence correlation spectroscopy. J Biomol Screen 1999; 4: 335–353.

    Article  PubMed  CAS  Google Scholar 

  26. Archer R. Faculty or factory? Why industrializing drug discovery is inevitable. J Biomol Screen 1999; 5: 235–237.

    Article  Google Scholar 

  27. Wolcke J, Ullmann D. Miniaturized HTS technologies-uHTS Drug Discov Today 2001; 6:637–646

    Google Scholar 

  28. Fox S, Wang H, Sopchack L, et al. High-Throughput Screening 2002: New Strategies and Technologies Moranga, CA: HighTech Business Decisions. 2002.

    Google Scholar 

  29. Li AP. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 2001; 6: 357–366.

    Article  PubMed  CAS  Google Scholar 

  30. Valkó K. Measurements and predictions of physicochemical properties. In: Darvas F, Dorman G, eds., High Throughput ADMETox Estimation: In Vitro and In Silico Approaches. Westborough, MA: Eaton. 2002: 1–24.

    Google Scholar 

  31. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability in human epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880–885.

    Article  PubMed  CAS  Google Scholar 

  32. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption. JMed Chem 1998; 41: 1007–1010.

    Article  CAS  Google Scholar 

  33. Crespi CL, Miller VP, Penman BW. High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 1998; 8: 457–471.

    CAS  Google Scholar 

  34. Slater K. Cytotoxicity tests for high throughput drug discovery Curr Opin Biotechnol 2001; 12:70–74

    Google Scholar 

  35. Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the salmonella/mammalian microsome mutagenicity test. Mutat Res 1975; 31: 347–367.

    Article  PubMed  CAS  Google Scholar 

  36. Krajcsi P, Drayas F. High-throughput in vitro toxicology. In: Darvas F, Dorman G, eds High Throughput ADMETox Estimation: In vitro and In Silico Approaches. Westborough, MA: Eaton. 2002:75–81

    Google Scholar 

  37. Netzer R, Ebneth A, Bischoff U, Pongs O. Screening lead compounds for QT interval prolongation Drug Discov Today 2001; 6:78–84

    Google Scholar 

  38. Tang W, Kang J, Wu X, et al. Development and evaluation of high throughput functional assay methods for hERG potassium channel. J Biomol Screen 2001; 6: 325–331.

    Article  PubMed  CAS  Google Scholar 

  39. Engels MFM, Venkatarangan P. Smart screening: approaches to efficient HTS Curr Opin Drug Discov Dev 2001; 4:275–283

    Google Scholar 

Download references

Authors
  1. Michael D. Boisclair PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Egan PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kety Huberman MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ralph Infantino BA
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oncology Discovery and Research, Genzyme Corporation, Framingham, MA, USA

    Beverly A. Teicher PhD (Vice President and Director of Oncology Portfolio) (Vice President and Director of Oncology Portfolio)

  2. Preclinical Sciences, Aton Pharma Inc., Tarrytown, NY, USA

    Paul A. Andrews PhD (Senior Director) (Senior Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Boisclair, M.D., Egan, D.A., Huberman, K., Infantino, R. (2004). High-Throughput Screening in Industry. In: Teicher, B.A., Andrews, P.A. (eds) Anticancer Drug Development Guide. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-739-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-739-0_2

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9841-7

  • Online ISBN: 978-1-59259-739-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation